Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ASML Holding NV (ASML) vs Illumina, Inc. (ILMN) Price & Performance

ASML Holding NVTrade
Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

ASML Holding NV vs Illumina, Inc. — how do they compare? ASML Holding NV trades at $1,806.21 (market cap $671.92B), while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: ASML Holding NV is far larger — about 23.2× Illumina, Inc.'s market cap, and ASML Holding NV pays a 0.52% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.

ASMLILMN
Market Cap
$671.92B$28.96B
Sector
TechnologyHealth
52-Week High
$1.99K$205.10
52-Week Low
$721.31$91.00
Enterprise Value
$665.45B$30.32B
Dividend Yield
0.52%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ASML Holding NV

ASML trades at $1,740.99, up 2.15% today, with a bullish technical signal and strong support near $1,721. The stock shows robust fundamentals with 2025 revenue of $32.67B and net income of $9.61B, though high valuation ratios like a P/E of 59.29 indicate premium pricing. Recent earnings beat expectations in Q1 and Q2 2026, and analyst consensus is bullish with a $2,390 price target.

Outlook remains positive driven by AI demand for semiconductor equipment, but risks include geopolitical tensions with China and high valuation sensitivity. Institutional sentiment is strong with 56.82% buy ratings, though competition and export curbs pose challenges to growth sustainability.

Illumina, Inc.

Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.

The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ASML Holding NV

Founded in 1984 and based in the Netherlands, ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photomask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a meaningful portion of the cost of making cutting-edge chips. Chipmakers require next-generation EUV lithography tools from ASML to continue past the 5-nanometer process node. ASML's products are used at every major semiconductor manufacturer, including Intel, Samsung, and TSMC.

Read more on ASML

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN